Compounds > lovastatin
Page last updated: 2024-08-23

lovastatin and Abnormalities, Drug-Induced

lovastatin has been researched along with Abnormalities, Drug-Induced in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's4 (57.14)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hoe, CM; Lankas, GR; Stoffregen, DA; Wise, LD1
Cukierski, MA; Lankas, GR; Wise, LD1
Gibb, H; Scialli, AR1
Edison, RJ; Muenke, M1
Burnett, DM; Cunningham, ML; Osborne, MJ; Pollack, PS; Shields, KE; Stepanavage, ME1
Bokelman, DL; MacDonald, JS; Minsker, DH; Robertson, RT1
Ghidini, A; Sicherer, S; Willner, J1

Other Studies

7 other study(ies) available for lovastatin and Abnormalities, Drug-Induced

ArticleYear
Juvenile toxicity assessment of open-acid lovastatin in rats.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2011, Volume: 92, Issue:4

    Topics: Abnormalities, Drug-Induced; Animals; Anticholesteremic Agents; Behavior, Animal; Body Weight; Brain; Female; Lovastatin; Male; Motor Activity; Nervous System Diseases; Pregnancy; Rats; Rats, Sprague-Dawley

2011
The role of maternal toxicity in lovastatin-induced developmental toxicity.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2004, Volume: 71, Issue:3

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Area Under Curve; Body Weight; Bone and Bones; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Embryo, Mammalian; Female; Fetal Weight; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Maternal Exposure; Organ Size; Pregnancy; Pregnancy, Animal; Rats; Teratogens; Time Factors; Weight Loss

2004
Statin drugs and congenital anomalies.
    American journal of medical genetics. Part A, 2005, Jun-01, Volume: 135, Issue:2

    Topics: Abnormalities, Drug-Induced; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lovastatin; Pregnancy; Pregnancy Outcome; Pyrroles; Simvastatin

2005
Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly.
    The New England journal of medicine, 2005, Jun-30, Volume: 352, Issue:26

    Topics: Abnormalities, Drug-Induced; Central Nervous System; Female; Heart Defects, Congenital; Holoprosencephaly; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lovastatin; Pregnancy; Pregnancy Trimester, First

2005
Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
    Birth defects research. Part A, Clinical and molecular teratology, 2005, Volume: 73, Issue:11

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Anticholesteremic Agents; Female; Fetal Death; Humans; Lovastatin; Maternal-Fetal Exchange; Pregnancy; Pregnancy Outcome; Prospective Studies; Retrospective Studies; Simvastatin

2005
Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase.
    Teratology, 1983, Volume: 28, Issue:3

    Topics: Abnormalities, Drug-Induced; Animals; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Naphthalenes; Pregnancy; Rats; Rats, Inbred Strains

1983
Congenital abnormalities (VATER) in baby born to mother using lovastatin.
    Lancet (London, England), 1992, Jun-06, Volume: 339, Issue:8806

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anus, Imperforate; Female; Humans; Infant, Newborn; Kidney; Lovastatin; Spine; Syndrome; Tracheoesophageal Fistula

1992